MPPE1 and neoplasm: However, this concept was already addressed in a publication of Salmon and colleagues, where they enhanced the tumor immunogenicity by the targeted manipulation of cDC1 precursors in the tumor.4 Providing cDC1s to cancer patients from alternative sources, rather than relying on their own precursors, could help overcome the limitations of immune checkpoint blockade.